Sundaram Multi Pap Reports Profit for Q2 FY26, Reversing Previous Losses
Sundaram Multi Pap reported a net profit of ₹83.01 Lacs for the quarter ended September 30, 2025, a significant turnaround from losses in prior periods, showing improved financial performance.
The announcement of a turnaround from net losses to a net profit is a significant positive development for the company's financial health and investor sentiment, likely leading to a high impact on its stock performance and market perception.
The company reported a net profit of ₹83.01 Lacs for the quarter ended September 30, 2025, a substantial improvement from net losses in the previous quarter and the corresponding quarter of the prior year. This turnaround from loss to profit indicates positive financial performance.
* Sundaram Multi Pap Limited has announced its Unaudited Standalone Financial Results for the quarter and half year ended September 30, 2025. * The results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on November 13, 2025. * The company reported a net profit of ₹83.01 Lacs after tax for the quarter ended September 30, 2025. * This compares to a net loss of ₹(44.38) Lacs in the previous quarter (June 30, 2025) and a net loss of ₹(183.46) Lacs in the corresponding quarter last year (September 30, 2024). * Total income from operations (net) for the quarter stood at ₹2,603.65 Lacs, an increase from ₹2,400.55 Lacs in the same period last year. * For the half year ended September 30, 2025, the net profit after tax was ₹38.63 Lacs, compared to a net loss of ₹(158.28) Lacs in the prior year's half-year period. * Basic and Diluted Earnings per Share (EPS) for the quarter was ₹0.02, and for the half year was ₹0.01. * An exceptional item consisting of interest income as per Ind AS 116 was noted. * The detailed financial results were published in Free Press Journal (English Edition) and Nav Shakti (Marathi Edition) on November 15, 2025, and are available on the stock exchange websites and the company's website.
What to do with a filing like this
Sundaram Multi Pap Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sundaram Multi Pap Limited. Read the original for the full detail.